MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
45.00
-0.62
-1.36%
Opening 09:36 04/30 EDT
OPEN
45.25
PREV CLOSE
45.62
HIGH
45.25
LOW
44.72
VOLUME
11.40K
TURNOVER
--
52 WEEK HIGH
60.60
52 WEEK LOW
24.78
MARKET CAP
2.76B
P/E (TTM)
10.64
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PTGX last week (0421-0425)?
Weekly Report · 2d ago
CFO Cashes In: Protagonist Therapeutics Stock Sale Shakes Market!
TipRanks · 6d ago
Weekly Report: what happened at PTGX last week (0414-0418)?
Weekly Report · 04/21 11:24
Weekly Report: what happened at PTGX last week (0407-0411)?
Weekly Report · 04/14 11:14
Protagonist Therapeutics’ Icotrokinra: A Promising Buy Rating Backed by Strong Efficacy, Safety, and Financial Prospects
TipRanks · 04/11 10:36
Protagonist Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Dow Jones · 04/10 17:02
HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $80 Price Target
Benzinga · 04/10 16:52
Protagonist Therapeutics: Promising Clinical Data and Strategic Expansion Drive Buy Rating
TipRanks · 04/10 16:05
More
About PTGX
More
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Recently
Symbol
Price
%Change

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.